MITOPE: Phase 2 evaluation of RSO-021, a novel mitochondrial PRX3 inhibitor, as a monotherapy and in combination with paclitaxel in patients with malignant pleural effusion due to mesothelioma or other advanced solid tumors
Naumov, G. Dulloo, S. Fennell, D. Lord, S. Thistlethwaite, Fiona Maskell, N. Popat, S. Blyth, K. Szlosarek, P. Aujayeb, A.
Naumov, G.
Dulloo, S.
Fennell, D.
Lord, S.
Thistlethwaite, Fiona
Maskell, N.
Popat, S.
Blyth, K.
Szlosarek, P.
Aujayeb, A.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Naumov G, Dulloo S, Fennell D, Lord S, Thistlethwaite F, Maskell N, et al. MITOPE: Phase 2 evaluation of RSO-021, a novel mitochondrial PRX3 inhibitor, as a monotherapy and in combination with paclitaxel in patients with malignant pleural effusion due to mesothelioma or other advanced solid tumors. EUROPEAN JOURNAL OF CANCER. 2024 OCT;211:S56-S. PubMed PMID: WOS:001345547300130. English.